| The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes |
|
Frontiers in Oncology |
Aplastic Anemia |
| Targeting the Microenvironment in MDS: The Final Frontier |
|
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
| Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
|
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
| Is blood transfusion safe during the COVID-19 pandemic? |
|
Future Science OA |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Immunosuppression and Growth Factors for Severe Aplastic Anemia: New Data for Old Questions |
|
Haematologica |
Aplastic Anemia |
| Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag |
|
Haematologica |
Aplastic Anemia |
| Granulocyte transfusions in severe aplastic anemia |
|
Haematologica |
Aplastic Anemia |
| Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Myelodysplastic Syndromes: Moving Towards Personalized Management |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
